Key terms
About KALV
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest KALV news
Mar 12
6:31am ET
KalVista awarded UK PIM designation for sebetralstat
Mar 12
6:26am ET
Buy Rating on KalVista Pharmaceuticals Backed by Sebetralstat’s Breakthrough in HAE Treatment
Mar 11
2:45pm ET
Buy Rating Affirmed for KalVista Pharmaceuticals on Strong Phase 3 Results and Solid Financial Position
Mar 11
6:33am ET
KalVista reports Q3 EPS (84c), consensus (77c)
Mar 11
12:47am ET
Buy Rating Reinforced by Strategic CEO Appointment and Promising Drug Development at KalVista Pharmaceuticals
Mar 07
6:52am ET
KalVista Pharmaceuticals Announces Executive Leadership Transition
Mar 07
6:32am ET
KalVista appoints Benjamin Palleiko as CEO
Feb 26
4:10pm ET
Analysts’ Top Healthcare Picks: KalVista Pharmaceuticals (KALV), Allakos (ALLK)
Feb 26
6:31am ET
KalVista presents additional Phase 3 KONFIDENT data at AAAAI meeting
Feb 20
6:51am ET
KalVista awarded UK Innovation Passport for sebetralstat
Feb 16
4:43pm ET
KalVista Pharmaceuticals Secures Funding to Advance Clinical Programs
Feb 16
4:23pm ET
KalVista CFO Palleiko sells 40,855 common shares
Feb 16
11:22am ET
Biotech Alert: Searches spiking for these stocks today
Feb 15
6:42am ET
KalVista 7.016M share Spot Secondary priced at $15.25
Feb 14
4:39pm ET
KalVista Pharmaceuticals Ends Stock Sale Agreement with Cantor
Feb 14
4:28pm ET
KalVista announces common stock, warrants offering
Feb 14
6:08am ET
KalVista price target raised to $24 from $16 at H.C. Wainwright
Feb 13
2:15pm ET
Buy Rating and Increased Price Target for KalVista Pharmaceuticals Following Sebetralstat’s Clinical Triumphs
Feb 13
7:13am ET
KalVista Pharmaceuticals’ Breakthrough in HAE Phase 3 Trial
Feb 07
8:41am ET
Leerink Partners Sticks to Its Buy Rating for KalVista Pharmaceuticals (KALV)
Feb 05
4:36am ET
Optimism Intact for KalVista Pharmaceuticals Despite Delay in KONFIDENT Study Data: Outperform Rating Reaffirmed
Feb 02
11:07am ET
Biotech Alert: Searches spiking for these stocks today
Feb 02
9:19am ET
KalVista shareholder buys 88,099 shares at $14.47
Feb 02
9:17am ET
KalVista shareholder buys 91,804 shares at $14.05
Jan 08
3:49pm ET
Fly Insider: Athira Pharma, Microstrategy among week’s notable insider trades
Jan 04
11:13am ET
Biotech Alert: Searches spiking for these stocks today
Dec 20
6:32am ET
KalVista announces publication of first oral factor XIIa data
No recent press releases are available for KALV
KALV Financials
Key terms
Ad Feedback
KALV Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
KALV Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
